M. Scholz et al. / European Journal of Medicinal Chemistry 46 (2011) 1131e1139
1139
[8] A.F. Armstrong, J.F. Valliant, The bioinorganic and medicinal chemistry of
carboranes: from new drug discovery to molecular imaging and therapy,
Dalton Trans. (2007) 4240e4251.
[32] A.S. Kalgutkar, B.C. Crews, S.W. Rowlinson, C. Garner, K. Seibert, L.J. Marnett,
Aspirin-like molecules that covalently inactivate cyclooxygenase-2, Science
280 (1998) 1268e1270.
[9] M.F. Hawthorne, D.C. Young, P.M. Garrett, D.A. Owen, S.G. Schwerin, F.N. Tebbe,
P.A. Wegner, Preparation and characterization of the (3)-1,2- and (3)-1,7-dicar-
badodecahydroundecaborate(-1) ions, J. Am. Chem. Soc. 90 (1968) 862e868.
[10] C.L. Powell, M. Schulze, S.J. Black, A.S. Thompson, M.D. Threadgill, Closo –> nido
cage degradation of 1-(substituted-phenyl)-1,2-dicarbadodecaborane(12)s in
wet DMSO under neutral conditions, Tetrahedron Lett. 48 (2007) 1251e1254.
[11] J. Yoo, J.W. Hwang, Y. Do, Facile and mild deboronation of o-carboranes using
cesium fluoride, Inorg. Chem. 40 (2001) 568e570.
[33] I. Ott, B. Kircher, C.P. Bagowski, D.H. Vlecken, E.B. Ott, J. Will, K. Bensdorf,
W.S. Sheldrick, R. Gust, Modulation of the biological properties of aspirin by
formation of a bioorganometallic derivative, Angew. Chem. Int. Ed. Engl. 48
(2009) 1160e1163.
[34] C. Davison, Salicylate metabolism in man, Ann. N. Y. Acad. Sci. 179 (1971)
249e268.
[35] J. Paterson, G. Baxter, J. Lawrence, G. Duthie, Is there a role for dietary salic-
ylates in health? Proc. Nutr. Soc. 65 (2006) 93e96.
[12] M.A. Fox, A.E. Goeta, A.K. Hughes, A.L. Johnson, Crystal and molecular struc-
tures of the nido-carborane anions, 7,9- and 2,9-C2B9H12, Dalton Trans. (2002)
2132e2141.
[13] Y. Endo, T. Sawabe, Y. Taoda, Electronic effects of icosahedral carboranes.
Retentive solvolysis of (1,2-dicarba-closo-dodecaboran-1-yl)benzyl p-tolue-
nesulfonates, J. Am. Chem. Soc. 122 (2000) 180e181.
[14] M.F. Hawthorne, D.C. Young, P.A. Wegner, Carbametallic boron hydride
derivatives. I. Apparent analogs of ferrocene and ferricinium ion, J. Am. Chem.
Soc. 87 (1965) 1818e1819.
[15] S. Bauer, S. Tschirschwitz, P. Lönnecke, R. Frank, B. Kirchener, M.L. Clarke,
E. Hey-Hawkins, Enantiomerically pure bis(phosphanyl)carbaborane(12)
compounds, Eur. J. Inorg. Chem. 2009 (2009) 2776e2788.
[36] Y. Taoda, T. Sawabe, Y. Endo, K. Yamaguchi, S. Fujii, H. Kagechika, Identifica-
tion of an intermediate in the deboronation of ortho-carborane: an adduct of
ortho-carborane with two nucleophiles on one boron atom, Chem. Commun.
(2008) 2049e2051.
[37] O.V. Volkov, E.A. Ll'inchik, V.V. Volkov, 11B NMR study of the tautomeric
transformations of the 7,8-dicarba- nido-undecaborane(11) adducts with
pyridine derivatives, J. Struct. Chem. 40 (1999) 402e405.
[38] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica,
J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity
assay for anticancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107e1112.
[39] S. Elmore, Apoptosis: a review of programmed cell death, Toxicol. Pathol. 35
(2007) 495e516.
[16] T.M. Keller, Oxidative protection of carbon fibers with poly(carbor-
aneesiloxaneeacetylene), Carbon 40 (2002) 225e229.
[17] J.F. Valliant, K.J. Guenther, A.S. King, P. Morel, P. Schaffer, O.O. Sogbein,
K.A. Stephenson, The medicinal chemistry of carboranes, Coord. Chem. Rev.
232 (2002) 173e230.
[40] T. Ogawa, K. Ohta, T. Iijima, T. Suzuki, S. Ohta, Y. Endo, Synthesis and biological
evaluation of p-carborane bisphenols and their derivatives: structureeactivity
relationship for estrogenic activity, Bioorg. Med. Chem. 17 (2009) 1109e1117.
[41] T. Ogawa, K. Ohta, T. Yoshimi, H. Yamazaki, T. Suzuki, S. Ohta, Y. Endo,
m-Carborane bisphenol structure as a pharmacophore for selective estrogen
receptor modulators, Bioorg. Med. Chem. Lett. 16 (2006) 3943e3946.
[42] C.G. Wermuth, C.R. Ganellin, P. Lindberg, L.A. Mitscher, Glossary of terms used
in medicinal chemistry (IUPAC Recommendations 1998), Pure Appl. Chem. 70
(1998) 1129e1143.
[43] M. Scholz, M. Steinhagen, J.T. Heiker, A.G. Beck-Sickinger, E. Hey-Hawkins,
Asborin inhibits aldo/keto reductase 1A1, ChemMedChem. 6 (2011) 89e93.
[44] I.S. Park, J.R. Jo, H. Hong, K.Y. Nam, J.B. Kim, S.H. Hwang, M.S. Choi, N.H. Ryu,
H.J. Jang, S.H. Lee, C.S. Kim, T.G. Kwon, G.Y. Park, J.W. Park, B.C. Jang, Aspirin
induces apoptosis in YD-8 human oral squamous carcinoma cells through
activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2
and AKT, Toxicol. in Vitro 24 (2010) 713e720.
[18] G.W. Kabalka, M.L. Yao, The synthesis and use of boronated amino acids for boron
neutron capture therapy, Anticancer Agents Med. Chem. 6 (2006) 111e125.
[19] M.F. Hawthorne, A. Maderna, Applications of radiolabeled boron clusters to
the diagnosis and treatment of cancer, Chem. Rev. 99 (1999) 3421e3434.
[20] Y. Endo, T. Yoshimi, Y. Yamakoshi, New estrogenic antagonists bearing
dicarba-closo-dodecaborane as a hydrophobic pharmacophore, Chem. Pharm.
Bull. 48 (2000) 312e314.
[21] J.F. Valliant, P. Schaffer, K.A. Stephenson, J.F. Britten, Synthesis of boroxifen,
a nido-carborane analogue of tamoxifen, J. Org. Chem. 67 (2002) 383e387.
[22] R.C. Reynolds, S.R. Campbell, R.G. Fairchild, R.L. Kisliuk, P.L. Micca, S.F. Queener,
J.M. Riordan, W.D. Sedwick, W.R. Waud, A.K. Leung, R.W. Dixon, W.J. Suling,
D.W. Borhani, Novel boron-containing, nonclassical antifolates: synthesis and
preliminary biological and structural evaluation, J. Med. Chem. 50 (2007) 3283e3289.
[23] R.L. Julius, O.K. Farha, J. Chiang, L.J. Perry, M.F. Hawthorne, Synthesis and
evaluation of transthyretin amyloidosis inhibitors containing carborane
pharmacophores, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4808e4813.
[24] M. Scholz, K. Bensdorf, R. Gust, E. Hey-Hawkins, Asborin: the carbaborane
analogue of aspirin, ChemMedChem 4 (2009) 746e748.
[45] N.R. Jana, NSAIDs and apoptosis, Cell. Mol. Life Sci. 65 (2008) 1295e1301.
[46] N. Ghosh, R. Chaki, V. Mandal, S.C. Mandal, COX-2 as a target for cancer
chemotherapy, Pharmacol. Rep. 62 (2010) 233e244.
[47] I.A. Voutsadakis, A. Patrikidou, K. Tsapakidis, A. Karagiannaki, E. Hatzidaki,
N.E. Stathakis, C.N. Papandreou, Additive inhibition of colorectal cancer cell
lines by aspirin and bortezomib, Int. J. Colorectal Dis. 25 (2010) 795e804.
[48] K.H. Yan, C.J. Yao, H.Y. Chang, G.M. Lai, A.L. Cheng, S.E. Chuang, The synergistic
anticancer effect of troglitazone combined with aspirin causes cell cycle arrest
and apoptosis in human lung cancer cells, Mol. Carcinog. 49 (2010) 235e246.
[49] D.L. Tab, J.K. Eng, J.R. Yates, Proteome Research: Mass Spectrometry. Springer
Verlag, Heidelberg, 2001.
[25] C.S. Williams, M. Mann, R.N. DuBois, The role of cyclooxygenases in inflam-
mation, cancer, and development, Oncogene 18 (1999) 7908e7916.
[26] B. Hinz, K. Brune, Cyclooxygenase-2 e 10 years later, J. Pharmacol. Exp. Ther.
300 (2002) 367e375.
[27] J.R. Vane, R.J. Flower, R.M. Botting, History of aspirin and its mechanism of
action, Stroke 21 (1990) IV12e23.
[50] SCALE3 ABSPACK: Empirical Absorption Correction, CrysAlis
Package. Oxford Diffraction Ltd, 2006.
e Software
[28] G.P. Hochgesang, S.W. Rowlinson, L.J. Marnett, Tyrosine-385 is critical for acet-
ylation of cyclooxygenase-2 by aspirin, J. Am. Chem. Soc. 122 (2000) 6514e6515.
[29] M. Lecomte, O. Laneuville, C. Ji, D.L. DeWitt, W.L. Smith, Acetylation of human
prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin, J. Biol.
Chem. 269 (1994) 13207e13215.
[51] A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, Completion and
refinement of crystal structures with SIR92, J. Appl. Crystallogr. 26 (1993)
343e350.
[52] G.M. Sheldrick, SHELXL-97, Program for the Refinement of Crystal Structures.
University of Göttingen, Göttingen (Germany), 1997.
[30] D.A. Wolters, M.P. Washburn, J.R. Yates 3rd, An automated multidimensional
protein identification technology for shotgun proteomics, Anal. Chem. 73
(2001) 5683e5690.
[53] A. Dietrich, T. Mueller, R. Paschke, B. Kalinowski, T. Behlendorf, F. Reipsch,
A. Fruehauf, H.J. Schmoll, C. Kloft, W. Voigt, 2-(4-(Tetrahydro-2H-pyran-2-
yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II):
a novel plat-
[31] B.S. Selinsky, K. Gupta, C.T. Sharkey, P.J. Loll, Structural analysis of NSAID binding
by prostaglandin H2 synthase: time-dependent and time-independent inhibi-
tors elicit identical enzyme conformations, Biochemistry 40 (2001) 5172e5180.
inum compound that overcomes cisplatin resistance and induces apoptosis by
mechanisms different from that of cisplatin, J. Med. Chem. 51 (2008)
5413e5422.